Fact check · Version 1 · Sources checked
“Thymosin alpha-1 reduced 28-day deaths in the large TESTS sepsis trial.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
The corrected result was 23.4% with thymosin alpha-1 and 24.1% with placebo. The study found no clear difference in 28-day deaths.
- What this answer is based on
- This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- The TESTS study randomized 1,106 adults with sepsis at 22 centers in China. The corrected analysis applies only to this study and outcome. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- What a study measured about people's health, symptoms, or ability to function.
Sources for this fact check
Show 2 sources
- Sources checked by
- Site editor · Editorial review